Guide · Updated November 2026
Best GLP-1 for Women: Hormones, PCOS, and Menopause
Tirzepatide (Mounjaro, Zepbound) produced more weight loss than semaglutide in trials: 20.9% on 15 mg in SURMOUNT-1 (NEJM, 2022) vs 14.9% on semaglutide 2.4 mg in STEP 1 (NEJM, 2021), and 20.2% vs 13.7% in the SURMOUNT-5 head-to-head (NEJM, 2025). Neither drug has been tested head to head in women with PCOS or in menopause specifically, so the choice should come down to your health history, tolerance, cost and your prescriber's advice.
PCOS affects an estimated 10 to 13% of reproductive-aged women and is a leading cause of infertility, according to the World Health Organization. Women with PCOS also face a higher long-term risk of obesity, insulin resistance and type 2 diabetes. GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro, Zepbound) reduce appetite, slow gastric emptying and improve blood sugar control. For women dealing with hormonal weight gain, the question is not only about the scale. It is also about insulin resistance, androgens and where fat is stored.
I have been on Mounjaro for over a year and track everything with DEXA scans. My experience is not the same as a woman with PCOS or someone going through menopause, so this guide leans on trial data rather than my own results.
Why Hormonal Weight Gain Responds Differently to GLP-1s
Standard weight loss advice often falls short for women with PCOS or menopause-related weight gain because it ignores the hormonal driver. Calorie restriction alone does not fix high insulin levels, and the weight often comes back.
GLP-1 medications act on several of the drivers:
- Insulin resistance. In the PCOS meta-analysis described below, GLP-1 drugs improved HOMA-IR, a common measure of insulin resistance. High insulin is linked to fat storage around the midsection and to excess androgen production in the ovaries.
- Androgen levels. The same meta-analysis found a slight drop in total testosterone and a rise in SHBG, the protein that binds testosterone. It did not find GLP-1 drugs better than metformin for free testosterone or DHEA-S.
- Central fat. Women with PCOS tend to store fat around the abdomen. In the meta-analysis, GLP-1 drugs reduced waist circumference. See our guide on fat loss vs weight loss for what changes in body composition.
- Appetite. GLP-1s act on appetite centers in the brain, which can help regardless of the hormonal cause of hunger.
For menopausal women, falling estrogen shifts fat toward the abdomen and can worsen insulin resistance. A GLP-1 will not replace estrogen, but it can help with the weight and blood sugar side of the picture.
Tirzepatide vs Semaglutide for Women: Head-to-Head Data
The SURMOUNT-5 trial gave us the first direct comparison of tirzepatide and semaglutide at maximum tolerated doses in adults with obesity and without diabetes. It was not a women-only trial.
| Metric | Tirzepatide (Mounjaro/Zepbound) | Semaglutide (Ozempic/Wegovy) |
|---|---|---|
| Average weight loss at 72 weeks | 20.2% | 13.7% |
| Waist circumference change | -18.4 cm | -13.0 cm |
| Stopped due to side effects | 6.1% | 8.0% |
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 agonist only |
Weight and waist figures come from the NEJM paper. Discontinuation figures come from Pharmacy Times coverage of the trial, which also notes the study was not designed to compare tolerability.
Three things matter for women specifically:
1. Muscle. In the SURMOUNT-1 body composition substudy of 160 people, about 25% of the weight lost on tirzepatide was lean mass and about 75% was fat (Diabetes, Obesity and Metabolism, 2025). We did not find a matching head-to-head DEXA comparison with semaglutide, so we do not claim one drug preserves more muscle than the other. Whichever drug you use, our muscle preservation protocol covers resistance training and protein.
2. Insulin and PCOS. Tirzepatide acts on both GIP and GLP-1 receptors, and it may have extra effects on insulin sensitivity, but there is no PCOS-specific head-to-head trial yet. A meta-analysis of GLP-1 drugs in PCOS (BMC Endocrine Disorders, 2023, 11 randomized trials, 840 patients) found better natural pregnancy rates and menstrual regularity, plus improvements in HOMA-IR, BMI and waist size. The trials in that analysis used older GLP-1 drugs, not tirzepatide.
3. Side effects. GI side effects are the most common reason people stop. In SURMOUNT-5, slightly fewer people stopped tirzepatide than semaglutide because of side effects (6.1% vs 8.0%). If you could not tolerate one drug, switching is a conversation to have with your prescriber.
Compare GLP-1 providers
Browse Provider Directory →Best GLP-1 for Women with PCOS
PCOS is the most common cause of anovulation worldwide (WHO). The core issue is often a loop: insulin resistance drives androgen excess, androgens promote abdominal fat, and abdominal fat worsens insulin resistance.
The BMC Endocrine Disorders meta-analysis of 11 randomized trials covering 840 women with PCOS found that GLP-1 receptor agonists improved natural pregnancy rates, menstrual regularity, BMI, waist circumference and HOMA-IR. In one trial of 176 overweight or obese women with PCOS, the natural pregnancy rate after exenatide (an older GLP-1) was 43.6% vs 18.7% after metformin during the second 12 weeks, when everyone took metformin (Liu et al., 2017).
Which GLP-1 to Choose for PCOS
There is no head-to-head trial in PCOS, so this is a judgment call for you and your prescriber. Points in favor of tirzepatide:
- Greater average weight loss in trials of adults with obesity (20.9% on 15 mg in SURMOUNT-1)
- Dual GIP/GLP-1 action, which may add to insulin effects, though this is not proven in PCOS
- Ahead of semaglutide in the SURMOUNT-5 head-to-head
Points in favor of semaglutide:
- 14.9% average weight loss in STEP 1, which is still substantial
- A longer research record, including more PCOS-specific studies of the GLP-1 class
- A self-pay Wegovy option at $199 to $349 a month as of Nov 4, 2026 (details below)
PCOS-Specific Considerations
Fertility and contraception. If you have PCOS and start a GLP-1, your fertility may improve. Both labels say these drugs should not be used in pregnancy. The Wegovy label says to stop at least 2 months before a planned pregnancy. The Zepbound label says tirzepatide may make birth control pills less effective, and advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase. Talk to your prescriber before trying to conceive. Our fertility guide covers this in more detail.
Metformin. Many women with PCOS already take metformin. A 2023 meta-analysis of nine exenatide trials found exenatide beat metformin on pregnancy rate, and three of those trials tested the two drugs together (BMC Endocrine Disorders, 2023). Do not stop or change metformin on your own. Ask your prescriber whether to continue it.
Androgen monitoring. You can ask your doctor whether to check testosterone and related hormones before starting and during treatment.
Best GLP-1 for Women in Menopause
Menopause changes the weight loss equation. Falling estrogen shifts fat toward the abdomen, can worsen insulin resistance and is linked to loss of muscle and bone.
Why GLP-1s Help During Menopause
- Abdominal fat. GLP-1 drugs reduce waist size along with weight, as SURMOUNT-5 showed.
- Blood sugar. GLP-1 drugs lower blood sugar and can help with insulin resistance.
- Appetite. Many women report more hunger and cravings around menopause. GLP-1s reduce appetite signaling.
Tirzepatide vs Semaglutide for Menopausal Women
Both work, and neither has been tested head to head in menopausal women. Because muscle and bone loss are already concerns after menopause, protecting lean mass matters whichever drug you choose.
Pair either medication with resistance training and enough protein. Ask your prescriber or a dietitian for a protein target that fits your kidneys and overall health. The body composition calculator can help you estimate your current lean mass. A DEXA scan can show whether you are keeping muscle. I wrote about my own DEXA results at six months for reference.
HRT and GLP-1s Together
Hormone replacement therapy (HRT) and GLP-1 medications are not mutually exclusive. HRT treats symptoms like hot flashes and sleep problems, while GLP-1s work on weight and blood sugar. The Zepbound label notes that tirzepatide delays gastric emptying and may affect how oral medicines are absorbed, and it names oral hormonal contraceptives specifically. Oral HRT is not named, but tell your prescriber about every medicine you take and ask whether a patch or gel makes more sense.
If you are considering both, Winona focuses on HRT for menopausal women and may be worth exploring alongside a GLP-1 provider.
Side Effects Women Should Watch For
The rates below come from each drug’s prescribing information. They come from different trials, so compare them with care.
| Side Effect | Tirzepatide (Zepbound label) | Semaglutide (Wegovy label) | Notes |
|---|---|---|---|
| Nausea | 25-29% (placebo 8%) | 44% (placebo 16%) | Usually during dose increases |
| Constipation | 11-17% (placebo 5%) | 24% (placebo 11%) | Fluids and fiber help |
| Hair loss | 4-5% (placebo 1%) | 3% (placebo 1%) | Often linked to rapid weight loss |
| Gallbladder problems | Listed as a warning | Listed as a warning | Risk rises with rapid weight loss |
Sources: Zepbound label and Wegovy label. Both labels also carry a boxed warning about thyroid C-cell tumors. Do not use either drug if you or a family member has had medullary thyroid carcinoma or MEN 2. Both labels also warn about pancreatitis, so get urgent care for severe stomach pain that does not go away.
Hair loss is the concern I hear about most from women on GLP-1s. Rapid weight loss can trigger temporary shedding called telogen effluvium. Our hair loss guide covers protein and other steps. See also our guide to supplements on GLP-1s.
Gallbladder problems deserve attention because rapid weight loss raises the risk of gallstones. The gallbladder guide covers warning signs.
For a full breakdown of what to expect month by month, see the side effects timeline guide.
How to Get Started: Cost and Access
Real out-of-pocket costs vary widely.
| Option | Monthly Cost (as of Nov 4, 2026) | Best For |
|---|---|---|
| Zepbound with commercial coverage + savings card | As little as $25 | Women whose plan covers Zepbound |
| Zepbound KwikPen self-pay | $299 (2.5 mg), $399 (5 mg), $449 (7.5 mg to 15 mg) | Brand-name tirzepatide without insurance (Lilly) |
| Wegovy pen self-pay (NovoCare) | $199 for the first 2 fills of 0.25 or 0.5 mg, then $349 | Brand-name semaglutide without insurance (NovoCare) |
| Wegovy pill self-pay (NovoCare) | $149 to $299 depending on dose | Women who prefer a pill |
| Compounded semaglutide or tirzepatide | Varies by provider | Not FDA-approved, legal status varies |
The Zepbound $449 price requires on-time refills, otherwise the higher doses cost $499 to $699. NovoCare says its pen pricing is a limited-time offer through December 31, 2026. Our cheapest GLP-1 guide has more pricing detail. If you have insurance, start with the insurance coverage guide.
Several telehealth providers serve women. See our reviews of Calibrate, Found, Ro and Hims, or compare them all in the provider directory.
The Bottom Line
Tirzepatide (Mounjaro/Zepbound) produced the most weight loss in trials of adults with obesity and beat semaglutide in the SURMOUNT-5 head-to-head. Semaglutide (Ozempic/Wegovy) is a solid option with a longer research record and a lower self-pay entry price. Neither has been tested head to head in PCOS or menopause. Whichever you choose, pair it with resistance training and protein, plan contraception carefully if you could get pregnant, and follow your prescriber’s dosing.
Start by comparing providers in the directory or use the body composition calculator to set a baseline.
FAQ
What is the best GLP-1 for women with PCOS?
There is no head-to-head trial in women with PCOS. In trials of adults with obesity, tirzepatide (Mounjaro or Zepbound) produced more weight loss than semaglutide (20.9% on 15 mg in SURMOUNT-1 vs 14.9% in STEP 1, and 20.2% vs 13.7% head to head in SURMOUNT-5). Semaglutide has more PCOS-specific research behind the GLP-1 class. Your prescriber can help you choose based on your health history and cost.
Can GLP-1 medications help with menopause weight gain?
Yes, they can help. GLP-1 medications reduce appetite, lower blood sugar and reduce waist size along with weight. They do not replace estrogen or treat hot flashes, and they have not been tested head to head in menopausal women.
Will a GLP-1 affect my period or fertility?
A meta-analysis of 11 trials found GLP-1 drugs improved menstrual regularity and natural pregnancy rates in women with PCOS, so fertility can improve. These drugs should not be used in pregnancy. The Wegovy label says to stop at least 2 months before a planned pregnancy. The Zepbound label says tirzepatide may make birth control pills less effective and advises a non-oral method or a backup barrier method for 4 weeks after starting and after each dose increase.
Is it safe to take a GLP-1 with HRT?
HRT is not listed as a named interaction, but GLP-1 drugs slow gastric emptying and the Zepbound label warns this may affect how oral medicines are absorbed. Many women use both. Tell your prescriber about all your medicines and ask whether a non-oral form of HRT makes sense.
Do GLP-1 side effects differ for women?
The main side effects (nausea, constipation, diarrhea) are the same for women and men. Hair loss and gallbladder problems are worth watching because both are linked to rapid weight loss. Slow dose increases set by your prescriber help most people manage GI side effects.
Related
Guides:
- Cheapest GLP-1 Online · Insurance Coverage · Side Effects
- Muscle Preservation Protocol · Protein Intake on GLP-1s · Fat Loss vs Weight Loss
- Ozempic Baby and Fertility · DEXA Scan Results · Hair Loss
Provider Reviews: Ro · Hims · Calibrate · Found · Winona
Compare: All Providers · Best GLP-1 Programs · All Guides
What we checked
This AI-assisted public-source desk check reviewed the NEJM SURMOUNT-1, STEP 1 and SURMOUNT-5 papers, the SURMOUNT-1 body composition analysis, a 2023 PCOS meta-analysis and a 2017 exenatide PCOS trial, the WHO PCOS fact sheet, the Zepbound and Wegovy prescribing information on DailyMed, and Lilly and NovoCare self-pay pricing pages on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.